-
Mashup Score: 1What is the role of CDK4/6 inhibitors in early breast cancer? - 7 month(s) ago
Michael Gnant, MD, FACS, FEBS, Medical University of Vienna, Vienna, Austria, gives an overview of current CDK4/6 inhibitors in early breast cancer. Recent trials such as the Phase II NATALEE trial (NCT03701334) of ribociclib plus endocrine therapy, the Phase II monarchE trial (NCT03155997) of abemaciclib and the Phase III Penelope-B trial (NCT01864746) of palbociclib have all demonstrated promising results. Prof. Gnant additionally talks on the PHERGain trial (NCT03161353) of dual HER2 blockade in early breast cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0ESMO Advanced Courses - 11 month(s) ago
ESMO is Europe’s leading medical oncology society, providing a professional network for its members and working with national societies across Europe.
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Great seeing you all at the ESMO Advanced Course on Deep Dive in #CDK4-6 Inhibitors Data in #BreastCancer in Dubai - this was our first Course on the subject in the area & an overwhelming success 🙌 See you soon at another Advanced Course 👉https://t.co/EnV4gf4AQ5 #BCSM @curijoey https://t.co/R3D9PasLHk
-
-
Mashup Score: 11Targeting CDK4 and CDK6 in cancer - Nature Reviews Cancer - 2 year(s) ago
Dysregulation of cyclin-dependent kinase 4 (CDK4) and CDK6, regulators of the cell cycle, favours the growth and survival of several cancer types. Owing to this, CDK4 and CDK6 inhibitors were developed and are currently approved for the treatment of advanced hormone receptor-positive breast cancer. This Review describes how we are only now beginning to fully understand their mechanisms of action…
Source: NatureCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#AACR2022 peeps & co, read up on argeting #CDK4 and #CDK6 in cancer in this @NatureRevCancer Review by @shomgoel, Bergholz & Zhao: https://t.co/fXiYS1TpXW @natrescancer @PeterMacRes @UniMelbMDHS https://t.co/xk1DvqAs57
-
-
Mashup Score: 5
The addition of CDKIs to fulvestrant resulted in a consistent overall survival benefit in all pooled patients and within most clinicopathological subgroups of interest. These findings support the existing standard of care of CDKIs plus fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative, advanced breast cancer.
Source: The Lancet OncologyCategories: Latest Headlines, Oncologists1Tweet-
Pooled survival analysis of #fulvestrant plus #cdk4/6i in metastatic ER+/HER2-#breastcancer #bcsm 👏👏@drjennifergao @SuparnaWedam @tmprowell and colleagues @FDAOncology https://t.co/62ltBBHUIj
-
-
Mashup Score: 0Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation - 3 year(s) ago
CDK4/6 inhibitors are approved to treat breast cancer and are in trials for other malignancies. We examined CDK4/6 inhibition in mouse and human CD8+ T cells during early stages of activation. Mice receiving tumor-specific CD8+ T cells treated with CDK4/6 inhibitors displayed increased T-cell persistence and immunologic memory. CDK4/6 inhibition upregulated MXD4, a negative regulator of MYC, in…
Source: Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
From the October issue: Inhibition of #CDK4/6 promotes CD8 T-cell memory formation. https://t.co/zgvTrPt0k5 @DanaFarber @DanaFarber_Hale #immunotherapy https://t.co/THDztmDPtC
-
-
Mashup Score: 0
In the Netherlands, inhibitors of cyclin-dependent kinase 4/6 (CDK 4/6) are eligible for reimbursement by health insurers. The present report describes implementation patterns of CDK4/6 inhibitors fo…
Source: Wiley Online LibraryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#BCAM2021 Virtual Issue | Marissa Meegdes, et al. The implementation of #CDK4/6 inhibitors and its impact on treatment choices in HR+/#HER2− advanced #breastcancer patients: A study of the Dutch SONABRE Registry 🔓➡️https://t.co/AvYOazSiDr @MaastrichtUMC @sandrageurts https://t.co/zsmFxSOyP0
-
-
Mashup Score: 4Inhibition of CDK4/6 promotes CD8 T-cell memory formation - 3 year(s) ago
CDK4/6 inhibitors are approved to treat breast cancer and are in trials for other malignancies. We examined CDK4/6 inhibition in mouse and human CD8 T cells during early stages of activation. Mice receiving tumor-specific CD8 T cells treated with CDK4/6 inhibitors displayed increased T cell persistence and immunologic memory. CDK4/6 inhibition upregulated Mxd4, a negative regulator of Myc, in…
Source: Cancer DiscoveryCategories: Latest Headlines, Oncologists1Tweet-
SCI leader Nathanael Gray & colleagues discovered CDK4/6 inhibitor therapy increases the frequency of #CD8 memory precursors and downregulates expression of #MYC target genes, and may augment long-term protective immunity for #cancerpatients. https://t.co/LBqmnzdhnb #CDK4 #CDK6
-
-
Mashup Score: 0Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway - 3 year(s) ago
Genetic aberrations in the cyclin-dependent kinase (CDK)4 pathway occur in 82% of patients with acral melanoma (AM), which is the predominant subtype …
Source: www.sciencedirect.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#MelanomaAwarenessMonth Guo & Colleagues report that #Palbociclib shows preliminary efficacy and acceptable safety profile in advanced acral #melanoma patients with genetic aberrations in the #CDK4 pathway: https://t.co/vfYmNf0mTH @EORTC https://t.co/oLIBG1YtLM
-
-
Mashup Score: 0Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large‐Scale Data to Inform Therapeutic Directions - 3 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large‐Scale Data to Inform Therapeutic Directions #CellCycle #CDK4 #CDK6 #PrecisionOncology #MolecularGenetics #CancerGenome #TargetedTherapy https://t.co/cPPfb0KhpN https://t.co/yuAm9JNbk6
-
-
Mashup Score: 0ESMO20 YO for YO: Highlights on adjuvant CDK4/6 inhibitors in early HR+/HER2- breast cancer - 3 year(s) ago
Drs Alexios Matikas and Matteo Lambertini discuss the results of two major randomized trials, presented at the ESMO Virtual Congress 2020, on the adjuvant use of cyclin dependent kinase 4/6 inhibitors
Source: SoundCloudCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMO20 YO for YO: Highlights on adjuvant #CDK4/6 inhibitors in early HR+/HER2- #breast_cancer #ESMO_Asia @myESMO @cczielinski @matteolambe https://t.co/WfezRI5N6i
-
📣October is Breast Cancer Awareness Month 📅 Check out this interview from #ASCO23, where @MichaelGnant discusses the role of #CDK4/6 inhibitors in early #breastcancer: ➡️https://t.co/c1RmY8FsgV🎥 #BCSM